Alexion Pharmaceuticals
ALXN
ALXN was delisted on the 20th of July, 2021.
600 hedge funds and large institutions have $26.2B invested in Alexion Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 65 funds opening new positions, 242 increasing their positions, 209 reducing their positions, and 56 closing their positions.
16% more first-time investments, than exits
New positions opened: 65 | Existing positions closed: 56
16% more repeat investments, than reductions
Existing positions increased: 242 | Existing positions reduced: 209
12% more capital invested
Capital invested by funds: $23.4B → $26.2B (+$2.74B)
6% more funds holding in top 10
Funds holding in top 10: 16 → 17 (+1)
1% more funds holding
Funds holding: 596 → 600 (+4)
11% less call options, than puts
Call options by funds: $308M | Put options by funds: $345M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$174M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$142M |
| 3 |
SSM
Sound Shore Management
Greenwich,
Connecticut
|
+$127M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$121M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$95.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$189M |
| 2 |
Jennison Associates
New York
|
-$171M |
| 3 |
EVM
Eaton Vance Management
Boston,
Massachusetts
|
-$132M |
| 4 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$108M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$103M |
ALXN Hedge Fund Activity: Q2 2018 in Review
600 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Alexion Pharmaceuticals (ALXN) for Q2 2018, worth a combined $26.2B — up 12% from $23.4B a quarter earlier.
Buyers outnumbered sellers: 65 funds opened new ALXN positions and 56 closed out — a net gain of 9 holders — while 242 added to existing stakes and 209 trimmed.
The largest buyer was Iridian Asset Management, adding an estimated $174M. The largest seller was BlackRock, cutting an estimated $189M.
- 600 institutional investors held Alexion Pharmaceuticals (ALXN) as of Q2 2018, up from 596 in Q1 2018.
- Funds reported $26.2B of Alexion Pharmaceuticals stock for Q2 2018, up 12% quarter-over-quarter.
- 65 funds opened new Alexion Pharmaceuticals positions in Q2 2018 and 56 closed out, a net change of +9 holders.
- The largest Alexion Pharmaceuticals buyer in Q2 2018 was Iridian Asset Management, an estimated $174M added.
- The largest Alexion Pharmaceuticals seller in Q2 2018 was BlackRock, an estimated $189M sold.
Based on aggregated 13F filings for Q2 2018.